Petryshen
Larry Petryshen, Salmon Arm CA
Patent application number | Description | Published |
---|---|---|
20120217133 | VARIABLE PHASE STEP FEEDER - Embodiments of the present disclosure generally provide a variable phase step feeder including a fixed set of stairs and a moving set of stairs. The fixed set of stairs may include a first fixed step, a second fixed step, and a third fixed step. The moving set of stairs may be interposed between the fixed set of stairs, and include a first moving step adapted to transport a workpiece from the first fixed step to the second fixed step and a second moving step adapted to transport the workpiece from the second fixed step to the third fixed step. The variable phase step feeder may further include a control mechanism for adjusting a phase relationship of the first moving step relative to the second moving step. | 08-30-2012 |
Tracey Petryshen, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20150057306 | COMPOSITIONS COMPRISING SCOPOLAMINE AND KETAMINE IN THE TREATMENT OF DEPRESSION - Described are compositions and methods for administering scopolamine and ketamine in the treatment of depression (e.g., Major Depressive Disorder and Treatment-Resistant Depression). | 02-26-2015 |
Tracey Lynn Petryshen, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110008468 | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders - Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium. | 01-13-2011 |